EA200970967A1 - Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip) - Google Patents

Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)

Info

Publication number
EA200970967A1
EA200970967A1 EA200970967A EA200970967A EA200970967A1 EA 200970967 A1 EA200970967 A1 EA 200970967A1 EA 200970967 A EA200970967 A EA 200970967A EA 200970967 A EA200970967 A EA 200970967A EA 200970967 A1 EA200970967 A1 EA 200970967A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sphingozin
indasols
oxadiazole
sip
agonists
Prior art date
Application number
EA200970967A
Other languages
English (en)
Other versions
EA016443B1 (ru
Inventor
Махмуд Ахмед
Джерард Мартин Пол Гиблин
Джэймс Майатт
Дэвид Нортон
Дин Энрю Риверс
Original Assignee
Глэксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0707617A external-priority patent/GB0707617D0/en
Priority claimed from GB0805993A external-priority patent/GB0805993D0/en
Application filed by Глэксо Груп Лимитед filed Critical Глэксо Груп Лимитед
Publication of EA200970967A1 publication Critical patent/EA200970967A1/ru
Publication of EA016443B1 publication Critical patent/EA016443B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Настоящее изобретение относится к соединениям формулы (I) или их солямобладающим фармакологической активностью, способам их получения, содержащим их фармацевтическим композициям и к их применению при лечении различных расстройств, опосредованных S1P1 рецепторами.
EA200970967A 2007-04-19 2008-04-17 Оксадиазолзамещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (s1p) EA016443B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0707617A GB0707617D0 (en) 2007-04-19 2007-04-19 Compounds
GB0805993A GB0805993D0 (en) 2008-04-02 2008-04-02 Compounds
PCT/EP2008/054647 WO2008128951A1 (en) 2007-04-19 2008-04-17 Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists

Publications (2)

Publication Number Publication Date
EA200970967A1 true EA200970967A1 (ru) 2010-02-26
EA016443B1 EA016443B1 (ru) 2012-05-30

Family

ID=39604751

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970967A EA016443B1 (ru) 2007-04-19 2008-04-17 Оксадиазолзамещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (s1p)

Country Status (25)

Country Link
US (1) US8324254B2 (ru)
EP (1) EP2137181B1 (ru)
JP (1) JP5313229B2 (ru)
KR (1) KR20090130062A (ru)
AR (1) AR066095A1 (ru)
AT (1) ATE500252T1 (ru)
AU (1) AU2008240773B2 (ru)
BR (1) BRPI0809472A2 (ru)
CA (1) CA2684385A1 (ru)
CL (1) CL2008001099A1 (ru)
CO (1) CO6321136A2 (ru)
CR (1) CR11119A (ru)
DE (1) DE602008005285D1 (ru)
DO (1) DOP2009000237A (ru)
EA (1) EA016443B1 (ru)
HK (1) HK1138001A1 (ru)
IL (1) IL200870A (ru)
JO (1) JO2686B1 (ru)
MA (1) MA31311B1 (ru)
MX (1) MX2009011155A (ru)
MY (1) MY146606A (ru)
NZ (1) NZ579595A (ru)
PE (1) PE20090150A1 (ru)
TW (1) TWI408137B (ru)
WO (1) WO2008128951A1 (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0709866B8 (pt) 2006-04-03 2021-05-25 Astellas Pharma Inc compostos héteros e composição farmacêutica compreendendo ditos compostos
JO2701B1 (en) * 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
EP2222668B1 (en) * 2007-12-18 2011-11-02 Arena Pharmaceuticals, Inc. Tetrahydrocyclopenta[b]indol-3-yl carboxylic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
CA2720631C (en) * 2008-04-04 2012-08-28 Eli Lilly And Company 3-indazolyl-4-pyridylisothiazoles
GB0807910D0 (en) * 2008-04-30 2008-06-04 Glaxo Group Ltd Compounds
SI2307007T1 (sl) * 2008-07-23 2014-11-28 Novartis Ag Modulatorji sfingozin 1 fosfatnega receptorja in njihova uporaba za zdravljenje mišičnega vnetja
KR20190004843A (ko) 2008-07-23 2019-01-14 아레나 파마슈티칼스, 인크. 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체
AU2009282747B2 (en) 2008-08-22 2015-04-02 Takeda Pharmaceutical Company Limited Polymeric benzyl carbonate-derivatives
US8415484B2 (en) 2008-08-27 2013-04-09 Arena Pharmaceuticals, Inc. Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
KR101406433B1 (ko) 2008-09-22 2014-06-13 카이맨 케미칼 컴파니 인코포레이티드 Ｈ-ｐｇｄｓ 억제제로서 다중헤테로아릴 화합물 및 프로스타글란딘 ｄ2 매개된 질병의 치료를 위한 그의 용도
BRPI0923178A2 (pt) 2008-12-18 2016-02-16 Merck Serono Sa derivados heterocíclicos de oxadiazol fundidos úteis para o tratamento de esclerose múltipla
GB0910691D0 (en) * 2009-06-19 2009-08-05 Glaxo Group Ltd Novel compounds
GB0910674D0 (en) 2009-06-19 2009-08-05 Glaxo Group Ltd Novel compounds
GB0910689D0 (en) * 2009-06-19 2009-08-05 Glaxo Wellcome Mfg Pte Ltd Novel compounds
US8399451B2 (en) * 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
JP2013514280A (ja) * 2009-12-18 2013-04-25 グラクソ グループ リミテッド スフィンゴシン１−リン酸１（ｓ１ｐ１）受容体アゴニストとして使用するためのオキサジアゾール置換インダゾール誘導体
EP4148045A1 (en) 2010-01-27 2023-03-15 Arena Pharmaceuticals, Inc. Intermediate compounds for the preparation of (r)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b] indol-3-yl)acetic acid and salts thereof
CA2789480A1 (en) 2010-03-03 2011-09-09 Arena Pharmaceuticals, Inc. Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
EP2809645A1 (en) 2012-02-03 2014-12-10 Novartis AG Process for preparing n-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester
JP2016028016A (ja) * 2012-12-12 2016-02-25 大日本住友製薬株式会社 オキサジアゾール誘導体とその医薬用途
CN105474014B (zh) 2013-08-20 2017-04-05 明治制果药业株式会社 S1p1受体激动剂的评价方法和筛选方法
MX2021011472A (es) 2015-01-06 2022-08-17 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
CN110545848A (zh) 2017-02-16 2019-12-06 艾尼纳制药公司 用于治疗具有肠外表现的炎症性肠病的化合物和方法
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
CN109100971B (zh) * 2018-08-20 2024-02-09 合肥华耀电子工业有限公司 一种带互锁功能的开关机时序控制电路
WO2020051378A1 (en) 2018-09-06 2020-03-12 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3939238A1 (de) 1989-11-28 1991-05-29 Bayer Ag Heterocyclisch substituierte acrylsaeureester
US5262416A (en) * 1990-01-28 1993-11-16 Bayer Aktiengesellschaft Pesticidal substituted 2-[6-(pyrimidinyl)-indol-1-yl]-acrylic esters
DE4002466A1 (de) * 1990-01-28 1991-10-10 Bayer Ag Substituierte 2-(6-(pyrimidinyl)-indo-l-yl)-acrylsaeureester
US5462943A (en) * 1990-01-28 1995-10-31 Bayer Aktiengesellschaft Substituted acetic acid esters useful as pesticides per se and as intermediates for substitued acrylic esters pesticides
US5523312A (en) * 1994-09-27 1996-06-04 Sterling Winthrop Inc. Antipicornaviral agents
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP2001199983A (ja) * 2000-01-18 2001-07-24 Teijin Ltd ベンズイミダゾール誘導体
CA2488117A1 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
WO2004096757A1 (en) * 2003-04-30 2004-11-11 Novartis Ag Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
WO2004103279A2 (en) * 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
WO2005032465A2 (en) * 2003-10-01 2005-04-14 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
US7605171B2 (en) * 2003-12-17 2009-10-20 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
JP5315611B2 (ja) 2004-06-23 2013-10-16 小野薬品工業株式会社 Ｓ１ｐ受容体結合能を有する化合物およびその用途
EP1804793A4 (en) * 2004-10-22 2010-03-31 Merck Sharp & Dohme 2- (ARYL) AZACYCLYLMETHYL-CARBOXYLATE, SULPHONATE, PHOSPHONATE, PHOSPHINATE AND HETEROCYCLES AS S1P RECEPTOR AGONISTS
AU2006216170B2 (en) * 2005-02-25 2012-02-09 Ono Pharmaceutical Co., Ltd. Indole compound and use thereof
DE602006003642D1 (en) * 2005-03-23 2008-12-24 Actelion Pharmaceuticals Ltd Neue thiophen-derivate als sphingosin-1-phosphat-1-rezeptorantagonisten
RU2382781C2 (ru) 2005-04-22 2010-02-27 Дайити Санкио Компани, Лимитед Гетероциклическое соединение
CA2610310A1 (en) * 2005-06-08 2006-12-14 Novartis Ag Polycyclic oxadiazoles or isoxazoles and their use as s1p receptor ligands
RU2008110949A (ru) * 2005-08-23 2009-09-27 Айрм Ллк (Bm) Соединения и композиции-иммуносупрессанты
GB0601744D0 (en) * 2006-01-27 2006-03-08 Novartis Ag Organic compounds
BRPI0709866B8 (pt) * 2006-04-03 2021-05-25 Astellas Pharma Inc compostos héteros e composição farmacêutica compreendendo ditos compostos
JO2701B1 (en) * 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles

Also Published As

Publication number Publication date
EA016443B1 (ru) 2012-05-30
US8324254B2 (en) 2012-12-04
ATE500252T1 (de) 2011-03-15
AU2008240773A1 (en) 2008-10-30
CR11119A (es) 2010-01-18
DE602008005285D1 (de) 2011-04-14
WO2008128951A1 (en) 2008-10-30
MA31311B1 (fr) 2010-04-01
IL200870A (en) 2013-08-29
TW200911794A (en) 2009-03-16
MY146606A (en) 2012-09-14
HK1138001A1 (en) 2010-08-13
AR066095A1 (es) 2009-07-22
DOP2009000237A (es) 2010-05-31
PE20090150A1 (es) 2009-05-08
IL200870A0 (en) 2010-05-17
JP5313229B2 (ja) 2013-10-09
CA2684385A1 (en) 2008-10-30
JO2686B1 (en) 2013-03-03
AU2008240773B2 (en) 2013-10-03
EP2137181B1 (en) 2011-03-02
CO6321136A2 (es) 2011-09-20
JP2010524886A (ja) 2010-07-22
KR20090130062A (ko) 2009-12-17
CL2008001099A1 (es) 2008-10-24
MX2009011155A (es) 2009-10-30
TWI408137B (zh) 2013-09-11
BRPI0809472A2 (pt) 2014-09-09
US20100113528A1 (en) 2010-05-06
NZ579595A (en) 2012-06-29
EP2137181A1 (en) 2009-12-30

Similar Documents

Publication Publication Date Title
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
EA200970612A1 (ru) Производные индола в качестве агонистов рецептора s1p1
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
EA201071169A1 (ru) ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA200900658A1 (ru) Производные индазолилэфиров или -амидов для лечения расстройств, опосредованных глюкокортиодными рецепторами
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA201100503A1 (ru) Глюкозидные производные и их применения
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
EA200970156A1 (ru) Пиридизиноновые производные
EA201001585A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
EA201070535A1 (ru) Новые агонисты глюкокортикоидных рецепторов
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
UA103617C2 (ru) Производные тиенопиридона как активаторы амр-активированной протеинкиназы (амрк)
WO2007084841A3 (en) Sulfonyl substituted 1h-indoles as ligands for the 5-hydroxytryptamine receptors
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
EA201200918A1 (ru) Производные пирролидин карбоновой кислоты как агонисты сопряженного с g-белком рецептора 43 (gpr43), фармацевтическая композиция и методы их использования при лечении метаболических нарушений
EA201100161A1 (ru) Производные хинуклидина карбоната и их медицинские композиции
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
MX2008002805A (es) Derivados de carboxamida como antagonistas del receptor muscarinico.
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ RU